Zdrowie i gospodarka · 15/04/2013
FDA Releases Draft Guidance on DNA Reactive Impurities in Pharmaceuticals
The FDA has made available a draft guidance document aimed at limiting carcinogenic risk from mutagenic impurities in pharmaceuticals, developed in collaboration with the International Conference on Harmonisation.
Source: Federal Register — Food and Drug AdministrationOpen original release →